JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 4 Publications

6 Customer Reviews

  • Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnMTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTN{M{[g{txO MYDTRW5ITVJ?
H4 cell NXz0c3FrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEnrVIZKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wOlcxPyEQvF2= NGDLfGpUSU6JRWK=
KGN cell NVfEbZV2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWruRnZwUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzODVizszN M{PtUHNCVkeHUh?=
786-0 cell NGXLUJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnvU3JKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44Ojl6OTFOwG0> M1riW3NCVkeHUh?=
769-P cell NV7DRmZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DZPWlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlgzOjJ2IN88US=> MUfTRW5ITVJ?
K5 cell NUnSXWJTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMU[yOEDPxE1? M4P6cnNCVkeHUh?=
MLMA cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFMzOTdizszN MlrCV2FPT0WU
MLMA cell Mn\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEXGcnVKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5PzB|IN88US=> NGPNRXJUSU6JRWK=
EW-7 cell Ml;lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?= NUPDOVZ6W0GQR1XS
SW1088 cell NVvHdGtHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnCO2lKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDB4NUGg{txO NXHzWotIW0GQR1XS
MC-IXC cell MneyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGPH[HJKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDd5OUKg{txO NYj5ZlF5W0GQR1XS
NCI-H2052 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnS1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwOVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB6MUW3JO69VQ>? NWLOcpFYW0GQR1XS
IGR-1 cell NYLIZnRmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGlIWi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6xNlAzQCEQvF2= MkHJV2FPT0WU
DSH1 cell NWTGWZloT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWTGeYY{UW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDJ7NjFOwG0> NXewNohCW0GQR1XS
PA-1 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWDEfW9LUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{ODB3Od88US=> M2HIeXNCVkeHUh?=
SK-MEL-3 cell Mo\xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OTJyNzFOwG0> M4faNXNCVkeHUh?=
SW900 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQTByIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz60PFI2PSEQvF2= MofLV2FPT0WU
CAKI-1 cell M1uz[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MonKTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzPzN6IN88US=> Mk\oV2FPT0WU
ES1 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4n1PWlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61Nlg6PyEQvF2= NF7CcHNUSU6JRWK=
SK-N-DZ cell NFK4W3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{OyW2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjJ3OUWg{txO Mn\lV2FPT0WU
RH-1 cell Mn\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIjS[mVKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ|IN88US=> NVTROVFqW0GQR1XS
ES8 cell NIrERnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGfifndKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlk4ODJizszN NEn5cmJUSU6JRWK=
NEC8 cell MkfQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEnae3VKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc3QTh{IN88US=> NHH0TYVUSU6JRWK=
LNCaP-Clone-FGC cell NUXKOnhOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXxdXdGUW6qaXLpeIlwdiCxZjDoeY1idiCOTlPhVE1EdG:wZT3GS2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh|NUO2JO69VQ>? NVjzNZVLW0GQR1XS
HCE-4 cell NXLJT4VnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYD0OWg2UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0> MmnaV2FPT0WU
U-118-MG cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmTwTY5pcWKrdHnvckBw\iCqdX3hckBWNTFzOD3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODFyNk[g{txO MlHYV2FPT0WU
GI-ME-N cell NF;JRVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVTFSoFTUW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1? NGHyUWdUSU6JRWK=
LB1047-RCC cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVqwfFBNUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOlE1OyEQvF2= MULTRW5ITVJ?
HT-1080 cell NV70ZWw{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4Tj[2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTl7MkGg{txO MUfTRW5ITVJ?
NB69 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHMTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zOVA1PyEQvF2= M17iRXNCVkeHUh?=
NCI-H1693 cell MlrCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MknITY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR2OEm1JO69VQ>? NIHxcWdUSU6JRWK=
HSC-3 cell MnnNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\iPGlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ6QTN|IN88US=> M1\lc3NCVkeHUh?=
MDA-MB-231 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV3OEm5JO69VQ>? NEnNNmRUSU6JRWK=
HOS cell NUfOOVExT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXafmhQUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5PjNizszN Mk\aV2FPT0WU
BT-549 cell MlvaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEWyVJpKdmirYnn0bY9vKG:oIHj1cYFvKEKWLUW0PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzh6NzFOwG0> NYqwcosxW0GQR1XS
NB17 cell NGTI[YtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHXHXmdKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QTd4IN88US=> NFfEdVJUSU6JRWK=
5637 cell MoLQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzvXmdWUW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QTZ3MjFOwG0> Mli0V2FPT0WU
OVCAR-8 cell Ml;YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2LPPGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTJ2M{[g{txO M1\mR3NCVkeHUh?=
G-402 cell NVnqeIM1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17pNGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk{ODN3IN88US=> NFnXbHpUSU6JRWK=
BB30-HNC cell M2nSRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYXQ[3ZnUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMEeyNVgh|ryP MmTIV2FPT0WU
HCC1806 cell M1HweGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXG1d4ROUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPFA3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOEOzPUDPxE1? NVLIboZUW0GQR1XS
COLO-800 cell NWHpRWtYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MknkTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTJ4NDFOwG0> NInnWnlUSU6JRWK=
FADU cell Ml32S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHLmXVhKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM3PTV5IN88US=> MlL5V2FPT0WU
NCI-H1651 cell NYXodYZVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M37FeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5|OUSwPUDPxE1? MkTLV2FPT0WU
AGS cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{DlSmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60O|cyOSEQvF2= MYnTRW5ITVJ?
CHP-212 cell M3HZWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6PDB7IN88US=> NEC2WlFUSU6JRWK=
YAPC cell MmfyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEOxRoRKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=> MWfTRW5ITVJ?
GOTO cell M1zVW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGdQXE9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS5OVc3KM7:TR?= M{LS[3NCVkeHUh?=
KYSE-510 cell MoezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml62TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=> MnzIV2FPT0WU
NCI-H2342 cell NGfBNHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIiyV2FKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUOyO|gh|ryP Mn70V2FPT0WU
BFTC-905 cell M4H2XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmTrTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjJ6M{Wg{txO NHTzT4dUSU6JRWK=
EW-16 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1XjVWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlczODl|IN88US=> MnjwV2FPT0WU
SK-MEL-30 cell M13YSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzR3NEOg{txO NXO0cW5xW0GQR1XS
HLE cell NWPOUo9xT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlnWTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke3OFg6KM7:TR?= MVTTRW5ITVJ?
T98G cell NFrCOXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUPJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5OlM2KM7:TR?= MlfkV2FPT0WU
HUTU-80 cell NXTTTWt6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg1OjJ6IN88US=> NU\ZTGFtW0GQR1XS
NOS-1 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3nTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVQ4PjZizszN MonmV2FPT0WU
SW780 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3LGOmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=> M2ro[XNCVkeHUh?=
KYSE-180 cell M1zncmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXnPWIs{UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE5OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUe2OVQh|ryP MWnTRW5ITVJ?
MDA-MB-361 cell NYrhZXNQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYTlO4pIUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65PFY1PyEQvF2= MkPYV2FPT0WU
SNU-C2B cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrLTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF|ODFOwG0> MUXTRW5ITVJ?
NCI-H661 cell NXTIVZNQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlnHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvODZ7NDFOwG0> MXHTRW5ITVJ?
OE33 cell NESzOWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEf3XlJKdmirYnn0bY9vKG:oIHj1cYFvKE:HM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE1Ozh7IN88US=> NWDxUnBTW0GQR1XS
TYK-nu cell M1Lq[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWTJcohq[mm2aX;uJI9nKGi3bXHuJHR[Uy2wdTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNlE5PjNizszN MXjTRW5ITVJ?
COLO-792 cell NHPoPZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfKclBtUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMkWyNVkh|ryP MV\TRW5ITVJ?
HEL cell Ml;1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzrTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkK2O|Yh|ryP MkCwV2FPT0WU
D-566MG cell M2\3NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX2zNXM1UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|M{S5NUDPxE1? NYPaeI1IW0GQR1XS
U031 cell NUH1d3p2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fRXmlvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFE5OTZizszN MWnTRW5ITVJ?
COR-L23 cell NHT1fYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGGyU4xKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR|M{S2JO69VQ>? MYDTRW5ITVJ?
NCI-H2452 cell MoXPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEOzU2hKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQ2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNUKyPFEh|ryP NIDiUJZUSU6JRWK=
BB65-RCC cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYLJcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PDV7IN88US=> NGnje3VUSU6JRWK=
CAL-33 cell NUGxZpR7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPafVlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjV4NkWg{txO NWTPblhXW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development L.L.C. November 2006 Phase 1
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products0

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID